Market Overview:

Preimplantation genetic diagnosis (PGD) is an assisted reproductive technology that allows for genetic testing of embryos created through in vitro fertilization before implantation in the uterus. PGD identifies genetic defects and chromosomal abnormalities to improve the chances of pregnancy and delivery of a healthy baby. It is primarily used for couples with a history of inherited disorders, repeat miscarriages due to genetic defects, advanced maternal age, and chromosomal abnormalities. PGD requires in vitro fertilization followed by the biopsy of one or two cells from the pre-embryos. The cells are then tested for genetic defects, chromosomal structure and translocations. Only healthy embryos are selected for implantation.

The Preimplantation Genetic Diagnosis Market is estimated to be valued at US$ 53.5 Mn or Mn in 2023 and is expected to exhibit a CAGR of 6.2% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Explorer more information on this topic, Please visit @ https://www.coherentmarketinsights.com/market-insight/preimplantation-genetic-diagnosis-market-698

Market Dynamics:

The growing demand for advanced screening of hereditary disorders and genetic abnormalities during pre-implantation stages is a major driver augmenting the preimplantation genetic diagnosis market growth. Additionally, the increasing cases of genetic disorders and rising infertility rates worldwide are further propelling the market expansion. According to the Centers for Disease Control and Prevention in 2020, approximately 12% of women aged 15 to 44 years in the United States have difficulty getting pregnant or carrying a pregnancy to term. Moreover, growing awareness regarding PGD technique and availability of favorable reimbursement policies are also fueling the market growth. However, strict regulatory frameworks as well as high procedural costs associated with PGD techniques may hamper the market growth.

Segment Analysis

The preimplantation genetic diagnosis market can be broadly categorized into two key segments – preimplantation genetic screening (PGS) and preimplantation genetic diagnosis (PGD). Among these, the preimplantation genetic screening segment dominates the market with the highest share. This is because PGS is generally considered a less invasive procedure as compared to PGD and provides information about chromosome numbers in embryos, enabling identification of embryos most capable of achieving pregnancy.

PEST Analysis

Political: Government policies promote adoption of assisted reproductive technologies. Regulations are in place to ensure ethical practice of preimplantation genetic procedures.
Economic: Rising infertility rates and increasing healthcare expenditures on fertility treatments drive market growth. However, the high cost of procedures can restrain the market to some extent.
Social: Growing social acceptance of IVF and other assisted reproduction technologies creates a conducive environment for advances in preimplantation genetic diagnosis.
Technological: Introduction of novel techniques like next-generation sequencing help improve diagnosis accuracy and effectiveness of procedures. Advancements enable analysis of entire genomes of embryos.

Key Takeaways

The global preimplantation genetic diagnosis market is expected to witness high growth, exhibiting CAGR of 6.2% over the forecast period, due to increasing infertility rates globally. North America currently dominates the market due to favorable reimbursement policies and technological advancements in the region. The Asia Pacific regional market is witnessing the fastest growth due to rising medical tourism, increasing public awareness, and improving healthcare facilities.

Key players operating in the preimplantation genetic diagnosis market are Amgen, Quest Diagnostics, Genentech Inc., Vertex, PerkinElmer, Inc., F. Hoffman-La-Roche Ltd, Thermo Fisher Scientific, Inc., and Laboratory Corporation of America Holdings, Abbott Laboratories, Illumina, Inc., Natera Inc., CooperGenomics Inc., Reproductive Genetics Institute, Inc., Genea Ltd., Invitae Corporation, and CombiMatrix Corporation. The global market is fragmented in nature with the presence of these key players.